Targeting Polo-like Kinase in Cancer Therapy: Fig. 1.
نویسندگان
چکیده
منابع مشابه
Targeting Polo-like kinase in cancer therapy.
Polo-like kinases (Plk) function in mitosis and maintaining DNA integrity. There are four family members, of which Plk1 represents a target for anticancer therapy. Plk1 is only expressed in dividing cells with peak expression during G2/M. Plk1 functions in multiple steps of mitosis, and is overexpressed in many tumor types. Mitotic arrest and inhibition of proliferation, apoptosis, and tumor gr...
متن کاملTargeting Polo - like Kinase 1 for the Treatment of Cancer
Plk1 levels start to rise significantly at the beginning of S phase, and peak after the G2/M transition [3]. Plk1 plays a critical role in centrosome maturation, kinetochore assembly, and bipolar spindle formation[4]. More importantly, Plk1 plays a key role in ensuring normal mitotic progression. It initiates mitotic entry and mitotic exit by phosphorylating Cyclin B, Cdc25c and by activating t...
متن کاملPolo-like kinase 1 as target for cancer therapy
Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor treatment efficacy of Plk1 inhibitors. Furthermore, the Plk1 enzyme is expressed only in dividing cells and is a major regulator of the cell cycle. It controls entry ...
متن کاملPolo-like kinase 4 inhibition: a strategy for cancer therapy?
In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.
متن کاملCancer Therapy: Preclinical Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma
Purpose: High-risk neuroblastoma remains a therapeutic challenge for pediatric oncologists. The Pololike kinase 1 (PLK1) is highly expressed in many human cancers and is a target of the novel small-molecule inhibitor BI 2536, which has shown promising anticancer activity in adult malignancies. Here, we investigated the effect of BI 2536 on neuroblastoma cells in vitro and in vivo to explore PLK...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2010
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-09-1380